Home > Cardiology > ACC 2019 > Vascular Medicine > Convincing evidence of the role of icosapent in reducing subsequent CV events

Convincing evidence of the role of icosapent in reducing subsequent CV events

Conference
ACC 2019
Trial
REDUCE-IT

A recent analysis of the REDUCE-IT trial has demonstrated that icosapent ethyl 2 g twice daily was superior to placebo in reducing triglycerides (TGs), cardiovascular (CV) events, and CV death among patients with high TGs and high cardiovascular risk [1].

Previous results from the REDUCE-IT showed that icosapent ethyl reduced the risk of a first ischaemic event by 25% (i.e. the primary composite endpoint of CV death, myocardial infarction, stroke, coronary revascularisation, or hospitalisation for unstable angina) [2]. The current REDUCE-IT analysis presented by Prof. Deepak Bhatt (Brigham and Women’s Hospital, USA) examined total ischaemic events.

The aim of the multicentre, randomised, double-blind REDUCE-IT trail was to assess the safety and benefit of icosapent ethyl compared with placebo in reducing total CV events among patients with high triglycerides. The study was set up by randomising 8,179 eligible patients 1:1 to either icosapent ethyl (...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on